Enzolytics IPF Immune™ Supports the Immune System
December 8th, 2022
The global immune health sector supplement market expects to increase annually by 6.6 percent through 2028.
“Immune boosting supplements recently have gained in popularity,” said Charles S. Cotropia, CEO of Enzolytics, Inc., a Texas biotech company. “We are talking about increasing sales from $20.18 billion in 2020 to $31.5 billion in 2028.
“The expected 6.6 percent CAGR is a very healthy trend,” he added. “More people are being proactive rather than reactive when it comes to their health, which is helping to drive the growth.”
Mr. Harry H. Zhabilov, Enzolytics’ Chief Scientific Officer of Enzolytics, said there are several factors driving the popularity of immune health supplements.
“We are more focused on our health than our parents or grandparents were. We live more active lifestyles than our mothers and fathers,” he said. “All of our interest in health has increased the number of people taking dietary supplements to record numbers. People are especially interested in immune health supplements.”
Fortune Business Insights reported that increased health awareness and disposable money also are generating increased sales of immune health supplements.
“We know people want to stay healthy and not wait until they are sick to take action,” Mr. Cotropia said. “This is why we developed Enzolytics IPF Immune™.
Enzolytics IPF Immune™, a nutritional supplement, is taken orally two consecutive days per week for eight consecutive weeks.
“We plan to launch Enzolytics IPF Immune™ in the coming months,” Mr. Cotropia said. “We are looking forward to helping people stay healthy.”
For more information, email email@example.com or visit enzolytics.com.
Disclaimer: The statements made regarding these products have not been evaluated by the Food and Drug Administration. This press release is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please check with your doctor. The news site hosting this press release is not associated with Enzolytics, Inc. It is merely publishing a press release announcement submitted by a company, without any stated or implied endorsement of the product or service.
1101 Raintree Circle
Allen, Texas 75013
Texas A&M University
Institute for Preclinical Studies
College Station, TX 77843-44
SOURCE: Enzolytics, Inc.
About Enzolytics, Inc.
Enzolytics Inc. is a Texas-based biotechnology company that focuses on therapeutics to treat numerous human health medical conditions. In addition to Enzolytics IPF Immune™, which will be on the U.S. market soon, the Company is developing other therapeutics for treating multiple infectious diseases, including monoclonal antibodies for treating COVID-19 and HIV, and anti-cancer therapeutics.